Today, a Director at AxoGen (AXGN), Mark Stephen Gold, bought shares of AXGN for $52.38K.
In addition to Mark Stephen Gold, 4 other AXGN executives reported Buy trades in the last month. Following this transaction Mark Stephen Gold’s holding in the company was increased by 1.17% to a total of $5.18 million.
See today’s analyst top recommended stocks >>
Based on AxoGen’s latest earnings report for the quarter ending June 30, the company posted quarterly revenue of $26.7 million and GAAP net loss of $7.02 million. In comparison, last year the company earned revenue of $20.58 million and had a GAAP net loss of $7.43 million. The company has a one-year high of $46.25 and a one-year low of $11.82. Currently, AxoGen has an average volume of 603.65K.
Four different firms, including BTIG and Canaccord Genuity, currently also have a Buy rating on the stock. Starting in August 2019, AXGN received 4 Buy ratings in a row.
The insider sentiment on AxoGen has been positive according to 32 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
Mark Stephen Gold’s trades have generated a 49.8% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provide products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity.